A N Boyko, V M Alifirova, I G Lukashevich, Z A Goncharova, I V Greshnova, L G Zaslavsky, S V Kotov, N A Malkova, G N Mishin, E V Parshina, I Ye Poverennova, L N Prakhova, S A Sivertseva, I V Smagina, N A Totolyan, Yu V Trinitatsky, T N Trushnikova, F A Khabirov, J Yu Chefranova, S G Shchur, V A Dudin, D V Pokhabov, A V Artemeva, A V Eremeeva, Yu N Linkova, A V Zinkina-Orikhan
OBJECTIVE: To evaluate the efficacy and safety of the anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose of 500 mg every 24 weeks during 100 weeks for the treatment of patients with multiple sclerosis (MS), including relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS (SPMS) with relapses. MATERIAL AND METHODS: The multicenter, randomized, double-blind and double-masked phase III clinical trial (CT) BCD-132-4/MIRANTIBUS (NCT05385744) included 338 adult patients with MS distributed in a 1:1 ratio into two groups: DIV 500 mg and teriflunomide (TRF) 14 mg...
2024: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova